Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32103| Title: | Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses. | Austin Authors: | Srinivasan, Ashish ;De Cruz, Peter P ;Sam, Melissa;Toong, Catherine;van Langenberg, Daniel R | Affiliation: | Department of Gastroenterology, Eastern Health, Melbourne, Australia. Gastroenterology and Hepatology Department of Immunopathology, NSW Health Pathology Liverpool Hospital, Sydney, Australia. |
Issue Date: | May-2023 | Date: | 2023 | Publication information: | Journal of Gastroenterology and Hepatology 2023-05; 38(5) | Abstract: | The optimal infliximab dose intensification strategy to address secondary loss of response (LOR) remains unclear. This study aimed to compare clinical and pharmacokinetic outcomes following (i) upfront infliximab re-induction with (ii) ongoing 6-weekly dose interval shortening (DIS), after the same number of doses. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32103 | DOI: | 10.1111/jgh.16133 | ORCID: | 0000-0001-5952-1570 0000-0002-3399-7236 0000-0003-3662-6307 |
Journal: | Journal of Gastroenterology and Hepatology | PubMed URL: | 36692034 | ISSN: | 1440-1746 | Type: | Journal Article | Subjects: | Anti-tumor necrosis factor Crohn's disease Dose intensification Secondary loss of response Tertiary nonresponse Tertiary response Therapeutic drug monitoring Ulcerative colitis |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.